Abstract：
BACKGROUND: Acquired critical illness weakness (AWCIP) is the most frequent neuromuscular disease in intensive care medicine departments. Its importance is given by the prolongation of hospital stay and the delayed recovery it causes to patients after hospitalization. The main objective of this study was to investigate the association between neuromuscular blocking agents and the development of acquired weakness in critically ill patients.
METHODS: We conducted a prospective study of 103 critically ill patients who were periodically monitored with electromyography.
RESULTS: The development of AWCIP was observed in 63 patients. The group of patients who developed AWCIP had a significantly higher utilization of neuromuscular blocking agents than the group who did not develop AWCIP [79.4% vs 50%, OR:3.85 (1.63-9.39), p <0.02]; likewise, this group of patients had a longer ICU stay [32 days vs 14 days, OR: 1.11 (1.06-1.17), p <0. 001] and a longer mechanical ventilation time [24 days vs 9 days, OR:1.2 (1.11-1.32), p <0.001].
CONCLUSIONS: Neuromuscular blocking agents are a factor associated with the occurrence of AWCIP.
METHODS: We conducted a prospective study of 103 critically ill patients who were periodically monitored with electromyography.
RESULTS: The development of AWCIP was observed in 63 patients. The group of patients who developed AWCIP had a significantly higher utilization of neuromuscular blocking agents than the group who did not develop AWCIP [79.4% vs 50%, OR:3.85 (1.63-9.39), p <0.02]; likewise, this group of patients had a longer ICU stay [32 days vs 14 days, OR: 1.11 (1.06-1.17), p <0. 001] and a longer mechanical ventilation time [24 days vs 9 days, OR:1.2 (1.11-1.32), p <0.001].
CONCLUSIONS: Neuromuscular blocking agents are a factor associated with the occurrence of AWCIP.
摘要：
背景：获得性危重病无力（AWCIP）是重症监护医学科中最常见的神经肌肉疾病。它的重要性在于住院时间的延长以及住院后患者的康复延迟。这项研究的主要目的是研究神经肌肉阻断剂与危重病人获得性虚弱发展之间的关系。
方法：我们对103例接受定期肌电图监测的危重患者进行了前瞻性研究。
结果：在63例患者中观察到AWCIP的发展。开发AWCIP的患者组的神经肌肉阻滞剂利用率明显高于未开发AWCIP的患者组[79.4％vs50％，OR：3.85（1.63-9.39），p<0.02]；同样，这组患者的ICU住院时间较长[32天比14天，OR：1.11（1.06-1.17），p<0。001]和更长的机械通气时间[24天比9天，OR：1.2（1.11-1.32），p<0.001]。
结论：神经肌肉阻断剂是与AWCIP发生相关的因素。
方法：我们对103例接受定期肌电图监测的危重患者进行了前瞻性研究。
结果：在63例患者中观察到AWCIP的发展。开发AWCIP的患者组的神经肌肉阻滞剂利用率明显高于未开发AWCIP的患者组[79.4％vs50％，OR：3.85（1.63-9.39），p<0.02]；同样，这组患者的ICU住院时间较长[32天比14天，OR：1.11（1.06-1.17），p<0。001]和更长的机械通气时间[24天比9天，OR：1.2（1.11-1.32），p<0.001]。
结论：神经肌肉阻断剂是与AWCIP发生相关的因素。
